首页 > 最新文献

Journal of Clinical and Experimental Hepatology最新文献

英文 中文
Liver Explantation in Difficult Scenarios. 困难情况下的肝移植。
IF 3.3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-03-01 Epub Date: 2024-11-28 DOI: 10.1016/j.jceh.2024.102461
Rajesh Dey, Shaleen Agarwal, Subash Gupta

Recipient hepatectomy is considered as the most difficult part of a liver transplant operation. This article describes techniques to deal with scenarios like massive caudate lobe, a recipient with a transjugular intrahepatic portosystemic shunt (TIPS) shunt in situ, a recipient with hepatocellular carcinoma, acute liver failure and a history of previous abdominal surgery.

受体肝切除术被认为是肝移植手术中最困难的部分。本文介绍了处理大量尾状叶,经颈静脉肝内门体分流术(TIPS)原位分流术的受体,肝细胞癌,急性肝衰竭和既往腹部手术史的受体的技术。
{"title":"Liver Explantation in Difficult Scenarios.","authors":"Rajesh Dey, Shaleen Agarwal, Subash Gupta","doi":"10.1016/j.jceh.2024.102461","DOIUrl":"10.1016/j.jceh.2024.102461","url":null,"abstract":"<p><p>Recipient hepatectomy is considered as the most difficult part of a liver transplant operation. This article describes techniques to deal with scenarios like massive caudate lobe, a recipient with a transjugular intrahepatic portosystemic shunt (TIPS) shunt <i>in situ</i>, a recipient with hepatocellular carcinoma, acute liver failure and a history of previous abdominal surgery.</p>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 2","pages":"102461"},"PeriodicalIF":3.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11714708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Special Techniques of Liver Transplantation: Living Donor Liver Transplantation With Right Posterior Sector Grafts and Extended Left Lobe Grafts; Auxiliary Partial Orthotopic Liver Transplantation, and Dual-Lobe Liver Transplantation. 肝移植的特殊技术:活体肝移植联合右后段和扩展左叶移植辅助部分原位肝移植和双叶肝移植。
IF 3.3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-03-01 Epub Date: 2024-11-15 DOI: 10.1016/j.jceh.2024.102451
Jasper S Rajasekar, Ashwin Rammohan, Mohamed Rela

Living donor liver transplantation (LDLT) constitutes the majority of liver transplants in Asia and advancements in LDLT techniques have expanded the range of allografts beyond the commonly used right lobe (RL). This review provides a comprehensive overview of lesser-known variants of allografts and LDLT techniques which include right posterior sector grafts (RPSG), dual-lobe liver transplantation (DLLT), auxiliary partial orthotopic liver transplantation (APOLT), and extended left lobe grafts with caudate concentrating on the technical aspects, current evidence, and their indications in contemporary practice of LDLT. The first section examines RPSGs, focussing on their potential as an alternative to RL grafts particularly when volumetric studies indicate a larger right posterior sector in donors. It addresses donor selection, surgical techniques, and potential complications. Next, the article explores DLLT, which optimizes graft volume through partial grafts from two donors. The emphasis is on the ethical considerations, surgical challenges, and haemodynamic risks, such as graft atrophy, highlighting the importance of careful donor selection and meticulous planning. The section on APOLT covers its application in treating acute liver failure (ALF) and metabolic liver diseases. The technique's ability to support liver function in ALF while avoiding long-term immunosuppression when the native liver regenerates is discussed, along with patient selection criteria and follow-up requirements. Finally, the review addresses left lobe grafts with caudate used in smaller adults and older children to increase functional graft volume and improve outcomes.

活体供肝移植(LDLT)是亚洲肝脏移植的主要形式,LDLT技术的进步扩大了同种异体移植的范围,超出了常用的右叶(RL)。本文综述了一些鲜为人知的同种异体移植物和LDLT技术,包括右后段移植物(RPSG)、双叶肝移植(DLLT)、辅助部分原位肝移植(APOLT)和带尾状核的扩展左叶移植物,重点介绍了技术方面、目前的证据及其在当代LDLT实践中的适应症。第一部分研究rpsg,重点关注其作为RL移植物的替代方案的潜力,特别是当体积研究表明供体右侧后段较大时。它涉及供体选择,手术技术和潜在的并发症。接下来,文章探讨了DLLT,它通过两个供体的部分移植物来优化移植物体积。重点是伦理考虑、手术挑战和血流动力学风险,如移植物萎缩,强调仔细选择供体和精心规划的重要性。APOLT部分涵盖了其在治疗急性肝衰竭(ALF)和代谢性肝病中的应用。讨论了该技术在ALF中支持肝功能的能力,同时避免了天然肝脏再生时的长期免疫抑制,以及患者选择标准和随访要求。最后,本文综述了带尾状核的左叶移植物在小个子成人和大龄儿童中的应用,以增加移植物的功能体积并改善预后。
{"title":"Special Techniques of Liver Transplantation: Living Donor Liver Transplantation With Right Posterior Sector Grafts and Extended Left Lobe Grafts; Auxiliary Partial Orthotopic Liver Transplantation, and Dual-Lobe Liver Transplantation.","authors":"Jasper S Rajasekar, Ashwin Rammohan, Mohamed Rela","doi":"10.1016/j.jceh.2024.102451","DOIUrl":"10.1016/j.jceh.2024.102451","url":null,"abstract":"<p><p>Living donor liver transplantation (LDLT) constitutes the majority of liver transplants in Asia and advancements in LDLT techniques have expanded the range of allografts beyond the commonly used right lobe (RL). This review provides a comprehensive overview of lesser-known variants of allografts and LDLT techniques which include right posterior sector grafts (RPSG), dual-lobe liver transplantation (DLLT), auxiliary partial orthotopic liver transplantation (APOLT), and extended left lobe grafts with caudate concentrating on the technical aspects, current evidence, and their indications in contemporary practice of LDLT. The first section examines RPSGs, focussing on their potential as an alternative to RL grafts particularly when volumetric studies indicate a larger right posterior sector in donors. It addresses donor selection, surgical techniques, and potential complications. Next, the article explores DLLT, which optimizes graft volume through partial grafts from two donors. The emphasis is on the ethical considerations, surgical challenges, and haemodynamic risks, such as graft atrophy, highlighting the importance of careful donor selection and meticulous planning. The section on APOLT covers its application in treating acute liver failure (ALF) and metabolic liver diseases. The technique's ability to support liver function in ALF while avoiding long-term immunosuppression when the native liver regenerates is discussed, along with patient selection criteria and follow-up requirements. Finally, the review addresses left lobe grafts with caudate used in smaller adults and older children to increase functional graft volume and improve outcomes.</p>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 2","pages":"102451"},"PeriodicalIF":3.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tofacitinib-induced Hepatitis and Tuberculosis: A Case of Two Rare Adverse Events in a Single Patient. 托法替尼引起的肝炎和结核病:一例罕见的不良事件在一个病人。
IF 3.3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-03-01 Epub Date: 2024-11-28 DOI: 10.1016/j.jceh.2024.102457
Kamlesh Taori, Sanjay Kumar, Mayankbhushan Pateriya, Naveen Tmu
{"title":"Tofacitinib-induced Hepatitis and Tuberculosis: A Case of Two Rare Adverse Events in a Single Patient.","authors":"Kamlesh Taori, Sanjay Kumar, Mayankbhushan Pateriya, Naveen Tmu","doi":"10.1016/j.jceh.2024.102457","DOIUrl":"https://doi.org/10.1016/j.jceh.2024.102457","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 2","pages":"102457"},"PeriodicalIF":3.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Preoperative Recipient Portal Vein Thrombosis in Living-donor Liver Transplantation. 活体肝移植术前受体门静脉血栓的处理。
IF 3.3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-03-01 Epub Date: 2024-11-13 DOI: 10.1016/j.jceh.2024.102445
Vivek Rajendran, Danny Joy, Sudheer Mohammed, Biju Chandran, Mathew Jacob

Portal vein thrombosis (PVT) occurs as a part of the natural history of cirrhosis in up to 15% of patients with cirrhosis. In the initial days, PVT was considered a contraindication to liver transplantation, but now with advanced techniques and perioperative management, patients with complex PVT also undergo living-donor liver transplantation (LDLT) with a similar outcome. This review provides a comprehensive overview of methods to proceed with liver transplantation when the recipient has PVT. Preoperatively, anticoagulation remains the mainstay of treatment, with transjugular intrahepatic portosystemic shunt (TIPS) playing an adjunct role in preparing patients for liver transplantation. In all patients, thrombectomy with re-establishment of physiological portal flow is the initial step. In patients where flow cannot be established, other physiological or nonphysiological means are employed, especially in complex PVT. Patients with grade III/IV PVT have worse outcomes (graft failure, mortality, recurrence) than those with lower-grade PVT. Physiological reconstruction is the method of choice, whereas non-physiological means are used as a bailout procedure.

门静脉血栓形成(PVT)作为肝硬化自然病史的一部分发生在高达15%的肝硬化患者中。最初,PVT被认为是肝移植的禁忌症,但现在随着先进的技术和围手术期管理,复杂PVT患者也接受活体供肝移植(LDLT),结果相似。本文综述了在受者有pvt时进行肝移植的方法。术前,抗凝仍然是主要的治疗方法,经颈静脉肝内门静脉分流术(TIPS)在准备肝移植患者中起辅助作用。在所有患者中,取栓重建门静脉生理性血流是第一步。在不能建立血流的患者中,采用其他生理或非生理手段,特别是复杂的PVT。III/IV级PVT患者的预后(移植物衰竭、死亡率、复发)比低级别PVT患者更差。生理重建是首选方法,而非生理手段被用作救助程序。
{"title":"Management of Preoperative Recipient Portal Vein Thrombosis in Living-donor Liver Transplantation.","authors":"Vivek Rajendran, Danny Joy, Sudheer Mohammed, Biju Chandran, Mathew Jacob","doi":"10.1016/j.jceh.2024.102445","DOIUrl":"10.1016/j.jceh.2024.102445","url":null,"abstract":"<p><p>Portal vein thrombosis (PVT) occurs as a part of the natural history of cirrhosis in up to 15% of patients with cirrhosis. In the initial days, PVT was considered a contraindication to liver transplantation, but now with advanced techniques and perioperative management, patients with complex PVT also undergo living-donor liver transplantation (LDLT) with a similar outcome. This review provides a comprehensive overview of methods to proceed with liver transplantation when the recipient has PVT. Preoperatively, anticoagulation remains the mainstay of treatment, with transjugular intrahepatic portosystemic shunt (TIPS) playing an adjunct role in preparing patients for liver transplantation. In all patients, thrombectomy with re-establishment of physiological portal flow is the initial step. In patients where flow cannot be established, other physiological or nonphysiological means are employed, especially in complex PVT. Patients with grade III/IV PVT have worse outcomes (graft failure, mortality, recurrence) than those with lower-grade PVT. Physiological reconstruction is the method of choice, whereas non-physiological means are used as a bailout procedure.</p>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 2","pages":"102445"},"PeriodicalIF":3.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11714416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MASLD, MLA Pesarattu and Other Developments. MASLD, MLA Pesarattu和其他发展。
IF 3.3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-01 Epub Date: 2024-11-22 DOI: 10.1016/j.jceh.2024.102465
Anil C Anand
{"title":"MASLD, MLA Pesarattu and Other Developments.","authors":"Anil C Anand","doi":"10.1016/j.jceh.2024.102465","DOIUrl":"10.1016/j.jceh.2024.102465","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 1","pages":"102465"},"PeriodicalIF":3.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11663955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142885575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genes of DLK1-DIO3 Locus and miR-379/656 Cluster is a Potential Diagnostic and Prognostic Marker in Patients With Hepatocellular Carcinoma: A Systems Biology Study DLK1-DIO3位点和miR-379/656簇基因是肝细胞癌患者的潜在诊断和预后标志物:一项系统生物学研究
IF 3.3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-12 DOI: 10.1016/j.jceh.2024.102450
Shreyas H. Karunakara , Rohit Mehtani , Shama P. Kabekkodu , Divya P. Kumar , Prasanna K. Santhekadur

Background

Hepatocellular carcinoma is the sixth most common malignancy reported globally. This highlights the need for reliable biomarkers that can be employed for diagnostic and prognostic applications. The present study aimed to classify and characterize the clinical potential of delta like non-canonical Notch ligand 1–type III iodothyronine deiodinase (DLK1-DIO3) and miR-379/656 cluster genes in hepatocellular carcinoma.

Methods

We extensively studied the clinical potential of DLK1-DIO3 genes through a comprehensive systems biology approach and assessed the diagnostic and prognostic potential of the genes associated with the region. Additionally, we have predicted the gene targets of the miR-379/656 cluster associated with the locus and have identified the gene ontology, pathway, and disease associations.

Results

We report this region as a potential biomarker for hepatocellular carcinoma. About thirty clustered miRNAs, a long-non-coding RNA, and two coding genes of the region were underexpressed in tumors. The receiver operating characteristic analysis identified 11 clustered miRNAs with diagnostic potential. Survival analyses identified maternally expressed gene 3 and the miR-379/656 cluster as prognostically significant. Further, the random forest model predicted that the miRNA cluster classifies patients according to Tumor, Node, Metastasis (TNM) staging. Furthermore, overrepresentation analysis identified several key pathways, molecular functions, and biological processes associated with the cluster gene targets.

Conclusion

Our study suggests that DLK1-DIO3 genes, miR-379/656 cluster, and its target gene network might be potential diagnostic and prognostic markers for hepatocellular carcinoma management and therapy.
背景:肝细胞癌是全球第六大最常见的恶性肿瘤。这凸显了对可用于诊断和预后应用的可靠生物标志物的需求。本研究旨在对delta样非规范Notch配体1- III型碘甲状腺原氨酸脱碘酶(DLK1-DIO3)和miR-379/656簇基因在肝细胞癌中的临床潜力进行分类和表征。方法通过综合系统生物学方法广泛研究DLK1-DIO3基因的临床潜力,并评估与该区域相关的基因的诊断和预后潜力。此外,我们预测了与该位点相关的miR-379/656簇的基因靶点,并确定了基因本体、途径和疾病关联。结果我们报道该区域是肝细胞癌的潜在生物标志物。肿瘤中约有30个聚集的mirna、一个长链非编码RNA和两个编码基因表达不足。受者操作特征分析鉴定出11个具有诊断潜力的集群mirna。生存分析发现母体表达的基因3和miR-379/656簇具有预后意义。此外,随机森林模型预测miRNA簇根据肿瘤、淋巴结、转移(TNM)分期对患者进行分类。此外,过度代表性分析确定了与集群基因靶点相关的几个关键途径、分子功能和生物学过程。结论DLK1-DIO3基因、miR-379/656簇及其靶基因网络可能是肝细胞癌管理和治疗的潜在诊断和预后指标。
{"title":"Genes of DLK1-DIO3 Locus and miR-379/656 Cluster is a Potential Diagnostic and Prognostic Marker in Patients With Hepatocellular Carcinoma: A Systems Biology Study","authors":"Shreyas H. Karunakara ,&nbsp;Rohit Mehtani ,&nbsp;Shama P. Kabekkodu ,&nbsp;Divya P. Kumar ,&nbsp;Prasanna K. Santhekadur","doi":"10.1016/j.jceh.2024.102450","DOIUrl":"10.1016/j.jceh.2024.102450","url":null,"abstract":"<div><h3>Background</h3><div>Hepatocellular carcinoma is the sixth most common malignancy reported globally. This highlights the need for reliable biomarkers that can be employed for diagnostic and prognostic applications. The present study aimed to classify and characterize the clinical potential of delta like non-canonical Notch ligand 1–type III iodothyronine deiodinase (DLK1-DIO3) and miR-379/656 cluster genes in hepatocellular carcinoma.</div></div><div><h3>Methods</h3><div>We extensively studied the clinical potential of DLK1-DIO3 genes through a comprehensive systems biology approach and assessed the diagnostic and prognostic potential of the genes associated with the region. Additionally, we have predicted the gene targets of the miR-379/656 cluster associated with the locus and have identified the gene ontology, pathway, and disease associations.</div></div><div><h3>Results</h3><div>We report this region as a potential biomarker for hepatocellular carcinoma. About thirty clustered miRNAs, a long-non-coding RNA, and two coding genes of the region were underexpressed in tumors. The receiver operating characteristic analysis identified 11 clustered miRNAs with diagnostic potential. Survival analyses identified maternally expressed gene 3 and the miR-379/656 cluster as prognostically significant. Further, the random forest model predicted that the miRNA cluster classifies patients according to Tumor, Node, Metastasis (TNM) staging. Furthermore, overrepresentation analysis identified several key pathways, molecular functions, and biological processes associated with the cluster gene targets.</div></div><div><h3>Conclusion</h3><div>Our study suggests that DLK1-DIO3 genes, miR-379/656 cluster, and its target gene network might be potential diagnostic and prognostic markers for hepatocellular carcinoma management and therapy.</div></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 2","pages":"Article 102450"},"PeriodicalIF":3.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142743158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Toward Rational Strategies for Prevention of Bleeding During Invasive Procedures in Patients With Cirrhosis 探讨肝硬化患者有创手术中预防出血的合理策略
IF 3.3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-12 DOI: 10.1016/j.jceh.2024.102452
Ton Lisman
{"title":"Toward Rational Strategies for Prevention of Bleeding During Invasive Procedures in Patients With Cirrhosis","authors":"Ton Lisman","doi":"10.1016/j.jceh.2024.102452","DOIUrl":"10.1016/j.jceh.2024.102452","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 1","pages":"Article 102452"},"PeriodicalIF":3.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Issue Highlights 发行亮点
IF 3.3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-01 DOI: 10.1016/S0973-6883(24)01110-1
{"title":"Issue Highlights","authors":"","doi":"10.1016/S0973-6883(24)01110-1","DOIUrl":"10.1016/S0973-6883(24)01110-1","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"14 6","pages":"Article 102443"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The SVIN-Trial—Just Another Brick in the Wall? SVIN 试验--只是墙上的又一块砖?
IF 3.3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-30 DOI: 10.1016/j.jceh.2024.102449
Rohit Mehtani
{"title":"The SVIN-Trial—Just Another Brick in the Wall?","authors":"Rohit Mehtani","doi":"10.1016/j.jceh.2024.102449","DOIUrl":"10.1016/j.jceh.2024.102449","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 2","pages":"Article 102449"},"PeriodicalIF":3.3,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142702458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global Epidemiology of Hepatocellular Carcinoma 肝细胞癌的全球流行病学
IF 3.3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-28 DOI: 10.1016/j.jceh.2024.102446
Satender P. Singh, Tushar Madke, Phool Chand
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and a significant global health challenge due to its high mortality rate. The epidemiology of HCC is closely linked to the prevalence of chronic liver diseases, the predominant etiology being hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, alcohol consumption, and metabolic disorders such as metabolic dysfunction-associated steatotic liver disease (MASLD). HCC incidence varies widely globally, with the highest rates observed in East Asia and sub-Saharan Africa. This geographic disparity is largely attributed to the endemicity of HBV and HCV in these regions. In Western countries, the incidence of HCC has been rising, driven by increasing rates of alcohol abuse and the presence of steatosis liver disease. MASLD-associated HCC has a higher body mass index, a higher rate of type 2 diabetes mellitus, hyperlipidemia, hypertension, and association with cardiovascular diseases. Steatosis-associated HCC is also known to develop in the absence of cirrhosis, unlike alcohol-related liver disease and viral hepatitis. Prevention strategies vary by region, focusing on vaccination against HBV, antiviral treatments for HBV and HCV, alcohol moderation, and lifestyle interventions along with weight reduction to reduce obesity and incidence of MASLD-related HCC incidence.
肝细胞癌(HCC)是原发性肝癌中最常见的一种,因其死亡率高而成为全球健康的重大挑战。HCC的流行病学与慢性肝病的发病率密切相关,主要病因是乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)感染、饮酒和代谢紊乱,如代谢功能障碍相关性脂肪性肝病(MASLD)。全球 HCC 发病率差异很大,东亚和撒哈拉以南非洲地区的发病率最高。这种地域差异主要归因于 HBV 和 HCV 在这些地区的流行。在西方国家,由于酗酒和脂肪肝的发病率不断上升,HCC 的发病率也在不断上升。MASLD相关性HCC的体重指数较高,2型糖尿病、高脂血症、高血压的发病率较高,并且与心血管疾病相关。与酒精相关性肝病和病毒性肝炎不同,脂肪变性相关性 HCC 在没有肝硬化的情况下也会发生。预防策略因地区而异,重点是接种 HBV 疫苗、HBV 和 HCV 的抗病毒治疗、节制饮酒、生活方式干预以及减轻体重,以减少肥胖和 MASLD 相关 HCC 的发病率。
{"title":"Global Epidemiology of Hepatocellular Carcinoma","authors":"Satender P. Singh,&nbsp;Tushar Madke,&nbsp;Phool Chand","doi":"10.1016/j.jceh.2024.102446","DOIUrl":"10.1016/j.jceh.2024.102446","url":null,"abstract":"<div><div>Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and a significant global health challenge due to its high mortality rate. The epidemiology of HCC is closely linked to the prevalence of chronic liver diseases, the predominant etiology being hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, alcohol consumption, and metabolic disorders such as metabolic dysfunction-associated steatotic liver disease (MASLD). HCC incidence varies widely globally, with the highest rates observed in East Asia and sub-Saharan Africa. This geographic disparity is largely attributed to the endemicity of HBV and HCV in these regions. In Western countries, the incidence of HCC has been rising, driven by increasing rates of alcohol abuse and the presence of steatosis liver disease. MASLD-associated HCC has a higher body mass index, a higher rate of type 2 diabetes mellitus, hyperlipidemia, hypertension, and association with cardiovascular diseases. Steatosis-associated HCC is also known to develop in the absence of cirrhosis, unlike alcohol-related liver disease and viral hepatitis. Prevention strategies vary by region, focusing on vaccination against HBV, antiviral treatments for HBV and HCV, alcohol moderation, and lifestyle interventions along with weight reduction to reduce obesity and incidence of MASLD-related HCC incidence.</div></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 2","pages":"Article 102446"},"PeriodicalIF":3.3,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142702456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical and Experimental Hepatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1